Raphael Dahmen

New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

R. H. A. Becker, Raphael Dahmen, Karin Bergmann et al. · Diabetes Care · 2014 · 405 citations

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

David Bode, Lukas Semmler, Paulina Wakula et al. · Cardiovascular Diabetology · 2021 · 108 citations · Full text

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

A. Steinstraesser, Ronald Schmidt, Karin Bergmann et al. · Diabetes Obesity and Metabolism · 2014 · 106 citations · Full text

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

Geremia B. Bolli, Annke D. Hahn, Ronald Schmidt et al. · Diabetes Care · 2012 · 104 citations · Full text

Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes

Timothy S. Bailey, Jeremy Pettus, Ronan Roussel et al. · Diabetes & Metabolism · 2017 · 94 citations · Full text